{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"This study was limited by lack of randomization due to the ultra-rare nature of blastic plasmacytoid dendritic cell neoplasm (BPDCN).\n\nPatients lacked established response criteria for BPDCN prior to STML-401-0114."},"pointOfContact":{"email":"clinicaltrials@menarinistemline.com","organization":"Stemline Therapeutics, Inc.","phone":"877-332-7967","title":"Ira Gupta, MD"}}